Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

44806 ARTÍCULOS , VIENDO DEL 2641 AL 2655

Microglial sTREM2 limits dyskinesia and acts on TrkB to support circuit plasticity

Castagnola C, Marongiu R, Wan Y, Torres ERS, Fan L, Jang MW, Cui Q, Kim J, Ye P, Zhu J, Panichkina A, Fall AB, Norman K, Gao B, Foxe N, Wong MY, Zhu D, Bhagwat M, Gong S, Orr AG, Lee FS, Surmeier DJ, Kaplitt MG, Gan L.

bioRxiv [Preprint]. 2026 May 7:2026.05.06.723382. doi: 10.64898/2026.05.06.723382.

The role and mechanisms of AMPK in neurovascular unit injury in Parkinson's disease

Liu B, Li N, Fan G, Guo Z, Wang K, Kong L.

Front Aging Neurosci. 2026 May 18;18:1790159. doi: 10.3389/fnagi.2026.1790159. eCollection 2026.

Nanotherapeutics Mediated Intranasal Delivery for Therapeutic Effect on Parkinson's Disease: Balancing Advancements and Challenges

Popli P, Rana B, Dhiman S, Singh I, Swami R, Singh TG.

Curr Drug Res Rev. 2026;18(1):16-37. doi: 10.2174/0125899775352044250519092112.

Integrating Long-Read Structural Variant Analysis with single-nucleus RNA-seq to Elucidate Gene Expression Effects in Disease

Kim K, Lin Z, Simmons SK, Parker J, Kearney M, Liao Z, Haywood N, Zhang J, Cline MP, Tuncali I, Sharma M, Serrano GE, Beach TG, Dong X, Popic V, Scherzer CR, Levin JZ.

bioRxiv [Preprint]. 2026 Mar 23:2026.03.20.713192. doi: 10.64898/2026.03.20.713192.

The NLRP3-α-Synuclein Circuit: A Core Driver and Therapeutic Target in Parkinson's Disease

Liu K, He Z, Zhang L, Wu YM, Xiao L.

J Inflamm Res. 2026 May 28;19:597280. doi: 10.2147/JIR.S597280. eCollection 2026.

Parkinson's Disease: Conventional Pharmacotherapy, Drug Delivery Innovations, and Emerging Therapeutic Targets

Raina D, Marwah C, Singh S, Akhtar A.

Brain Sci. 2026 Feb 14;16(2):226. doi: 10.3390/brainsci16020226.

The central cholinergic system as a therapeutic target in Parkinson's disease

Miller SJ, Yue JS, Bozal SB, Logan R, Hafler BP.

J Parkinsons Dis. 2026 May;16(3):391-415. doi: 10.1177/1877718X261427270. Epub 2026 Mar 19.

Copper Dyshomeostasis Affects α-Synuclein Clearance Mechanisms in Parkinson's Disease: Insights from In Vitro Models and Translational Evidence

Musarò D, Greco M, Lanza M, Damato M, Maffia M.

Int J Mol Sci. 2026 Mar 25;27(7):2993. doi: 10.3390/ijms27072993.

Interaction between Poly(ADP-ribose) polymerase-1 and α-synuclein pathology in Parkinson's disease

Zhang P, Li Q, Diao X, Zeng S.

Front Neurosci. 2026 Apr 13;20:1774158. doi: 10.3389/fnins.2026.1774158. eCollection 2026.

cGAS-STING activation in Parkinson's Disease: From mechanisms to Disease-Modifying therapeutic strategies

Solomon J, Mandal S, Aran KR.

Gene. 2026 Apr 5;985:150000. doi: 10.1016/j.gene.2026.150000. Epub 2026 Jan 5.

DYRK1A and Parkinson's disease, facts and hypotheses

Meijer L, Lindberg MF, Hogrel G, Khor B.

Neurobiol Dis. 2026 Apr 14;225:107379. doi: 10.1016/j.nbd.2026.107379. Online ahead of print.

Parkinson's disease as a disorder of synaptic raft integrity: A unified explanation for motor subtypes and non-motor symptoms

Sakoda S.

Neurochem Int. 2026 May 14;197:106177. doi: 10.1016/j.neuint.2026.106177. Online ahead of print.

Bibliometric analysis of the pathogenesis of Parkinson's Disease

Feng Y, Wang K, Guo X, Guo H, Gao X.

Pathol Res Pract. 2026 May;281:156417. doi: 10.1016/j.prp.2026.156417. Epub 2026 Feb 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias